Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Economic evaluation of gemcitabine plus cisplatin (GD) versus vinorelbine plus cisplatin plus Ifosfamide (NIP) in patients with locally advanced or metastatic non-small-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017
Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001
Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504 Source: Eur Respir J 2015; 46: 1440-1450 Year: 2015
Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma Source: Breathe 2008; 6: 165 Year: 2009
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Source: Eur Respir J 2006; 27: 1183-1189 Year: 2006
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019 Year: 2020
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer Source: Eur Respir J 2015; 46: 219-229 Year: 2015
A phase II study with gemcitabine (GEM) plus irinotecan (CPT11) in malignant mesothelioma (MM): preliminary report Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002
A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Pulmonary toxicity during chemotherapy with etopiside and carboplatin Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003